MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today anno...
Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, today announced the first collaboration in the Koneksa Academic Part...
Under the terms of the agreement, Hikma has an exclusive license to commercialise products in Rakuten Medical’s pipeline using its photoimmunotherapy...
Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broaden...
Under the collaboration, Boostimmune will have access to WuXi XDC's fully integrated, one-stop bioconjugate platform and extensive expertise in industry-le...
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the...
GenScript Biotech, the world's leading life-science research tools and services provider, and T-MAXIMUM Biotech, a biotechnology company pioneering univers...
By incorporating Sware's Res_Q platform, clients can enhance, streamline, and optimize the flow of content and data, effectively addressing the challenges ...
he three-year agreement includes a joint request to dismiss with prejudice the pending litigation between the companies, including any allegations related ...
Amarin Corporation plc (NASDAQ:AMRN) and Lotus Pharmaceuticals (1795:TT; “Lotus”) announced that the two companies have entered into a lo...
InSilicoTrials, a leading provider of artificial intelligence (AI) and simulation tools for drug and medical device development, has embarked on a ...
Through TrialHub's data intelligence gathering platform, EmVenio can easily identify optimal markets to attract clinical trial participants who are needed ...
SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) announced that Roche has determined that it will not exercis...
The partners continue working closely on matters concerning pending approval in the U.S. for AVT02, an interchangeable high-concentration biosimilar candid...
© 2025 Biopharma Boardroom. All Rights Reserved.
